EAST HANOVER, N.J., Sept. 19, 2013 /PRNewswire/ -- Novartis commemorates World CML Day by announcing the latest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy – a concept called treatment-free remission. More than 100 study sites are now enrolling patients to the trial program.
Since 2008, organizations around the world have recognized World CML Day1. The date, September 22 or 9/22, was chosen to symbolically represent the genetic material that is associated with CML – the missing section from chromosome 22 shifts to chromosome 9 and vice versa, in a phenomenon called "translocation2." Known as the Philadelphia chromosome, this genetic mutation is present in about 95% of CML patients3.
"As a leader in CML, Novartis is proud to support World CML Day through our continued dedication to ongoing research in this disease," said Herve Hoppenot, President, Novartis Oncology. "We are now exploring if the disease can be treated to a point where drug therapy is no longer needed, representing the next step in what may be possible for patients living with Ph+ CML."
Over the past decades, Novartis research in Ph+ CML has helped transform the disease from a fatal diagnosis to a chronic condition for many patients. Today, the company continues its long-standing commitment to the global CML community. The Novartis treatment-free remission clinical trial program[*] includes eight studies that are now underway and actively enrolling Ph+ CML patients in more than 100 global sites across 40 countries.
[*] In the Novartis treatment-free remission
Copyright©2012 PR Newswire.
All rights reserved